Effect of linaclotide in irritable bowel syndrome with constipation (IBS-C): A systematic review and meta-analysis

Neurogastroenterology and Motility

Volumn 26, Issue 4, 2014, Pages 499-509

  Atluri, D K ^a   Chandar, A K ^b,c,d   Bharucha, A E ^e   Falck Ytter, Y ^b,c,d  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^e MAYO CLINIC   (United States)

Author keywords

GRADE; IBS C; IBS QOL; Linaclotide; Meta analysis

Indexed keywords

LINACLOTIDE; PLACEBO; PEPTIDE;

ARTICLE; CINAHL; CLINICAL ASSESSMENT; COCHRANE LIBRARY; CONSTIPATION; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL QUALITY OF LIFE INDEX; GRADE METHOD; HUMAN; IRRITABLE BOWEL SYNDROME QUALITY OF LIFE SCALE; IRRITABLE BOWEL SYNDROME WITH CONSTIPATION; IRRITABLE COLON; LONG TERM CARE; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; PSYCINFO; QUALITY OF LIFE; QUALITY OF LIFE INDEX; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SYMPTOM; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ADULT; COMPLICATION; FEMALE; IRRITABLE BOWEL SYNDROME; MALE;

ADULT; CONSTIPATION; DIARRHEA; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; PEPTIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84896387978     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/nmo.12292     Document Type: Article

References (34)

1. Hungin AP, Whorwell PJ, Tack J, Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40, 000 subjects. Aliment Pharmacol Ther 2003; 17: 643-50.
2. Quigley EM, Bytzer P, Jones R, Mearin F. Irritable bowel syndrome: the burden and unmet needs in Europe. Dig Liver Dis 2006; 38: 717-23.
3. El-Serag HB, Olden K, Bjorkman D. Health-related quality of life among persons with irritable bowel syndrome: a systematic review. Aliment Pharmacol Ther 2002; 16: 1171-85.
4. Pare P, Gray J, Lam S et al. Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study. Clin Ther 2006; 28: 1726-35.
5. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006; 130: 1480-91.
6. Bharucha AE, Waldman SA. Taking a lesson from microbial diarrheagenesis in the management of chronic constipation. Gastroenterology 2010; 138: 813-7.
7. Bharucha AE, Linden DR. Linaclotide - a secretagogue and antihyperalgesic agent - what next? Neurogastroenterol Motil 2010; 22: 227-31.
8. Lembo AJ, Schneier HA, Shiff SJ et al. Two randomized trials of linaclotide for chronic constipation. N Engl J Med 2011; 365: 527-36.
9. Johnston JM, Kurtz CB, MacDougall JE et al. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. Gastroenterology 2010; 139: 1877-86, e2.
10. Chey WD, Lembo AJ, Lavins BJ et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol 2012; 107: 1702-12.
11. Rao S, Lembo AJ, Shiff SJ et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol 2012; 107: 1714-24.
12. Sayuk GS. Linaclotide: promising IBS-C efficacy in an era of provisional study endpoints. Am J Gastroenterol 2012; 107: 1726-9.
13. Bharucha AE, Pemberton JH, Locke GR. AGA practice guideline on constipation: technical review. Gastroenterology 2013; 144: 218-38.
14. Khan S, Chang L. Diagnosis and management of IBS. Nat Rev Gastroenterol Hepatol 2010; 7: 565-81.
15. Ford AC, Vandvik PO. Irritable bowel syndrome. Clin Evid (Online) 2012 Jan 6 [cited 2013 Sep 20]; pii: 0410. Available at: http://clinicalevidence.bmj.com/x/pdf/clinical-evidence/en-gb/systematic-review/0410.pdf.
16. Postmarket Drug Safety Information for Patients and Providers: Zelnorm (tegaserod maleate) Information [Internet]. Silver Spring, MD: U.S. Food and Drug Administration; [date unknown] [updated 2012 May 11; cited 2013 Sep 20]. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm103223.htm
17. Drossman DA, Chey WD, Johanson JF et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome-results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 2009; 29: 329-41.
18. Lubiprostone prescribing information [Internet]. Silver Spring, MD: U.S. Food and Drug Administration; [date unknown] [updated 2012 Nov; cited 2013 Sep 20]. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021908s010lbl.pdf
19. Guidance for Industry: Irritable Bowel Syndrome - Clinical Evaluation of Drugs for Treatment [Internet]. Silver Spring, MD: U.S. Food and Drug Administration; 2012 May [cited 2013 Sep 20]. Available at: http://www.fda.gov/downloads/Drugs/Guidances/UCM205269.pdf
20. Concept paper on the revision of the CHMP points to consider on the evaluation of medicinal products for the treatment of irritable bowel syndrome [Internet]. London, UK: European Medicines Agency; 2012 [cited 2013 Sep 20]; Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128217.pdf
21. Drossman D, Morris CB, Hu Y et al. Characterization of health related quality of life (HRQOL) for patients with functional bowel disorder (FBD) and its response to treatment. Am J Gastroenterol 2007; 102: 1442-53.
22. Drossman DA, Patrick DL, Whitehead WE et al. Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. Am J Gastroenterol 2000; 95: 999-1007.
23. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut 1999; 45(Suppl. 2): II43-7.
24. Review Manager (RevMan) [Computer program]. Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
25. Falck-Ytter Y, Kunz R, Guyatt GH, Schunemann HJ. How strong is the evidence? Am J Gastroenterol 2008; 103: 1334-8.
26. Guyatt GH, Oxman AD, Vist GE et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924-6.
27. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available at: www.cochrane-handbook.org
28. Carson R, Tourkodimitris S, Lewis BE, Johnston JM. Effect of linaclotide on quality of life in adults with irritable bowel syndrome with constipation: pooled results from two randomized, double-blind, placebo-controlled Phase 3 trials. Gastroenterology 2011; 140(5 Suppl. 1): S-51.
29. Rao SS, Quigley EM, Shiff SJ et al. Effect of linaclotide on severe abdominal symptoms in patients with irritable bowel syndrome with constipation. Clin Gastroenterol Hepatol 2013; pii: S1542-3565(13)01427-4. doi: 10.1016/j.cgh.2013.09.022.
30. Chey W, Rao S, Lembo A et al. Efficacy and safety of once-daily linaclotide administered orally for 12 weeks to patients with IBS-C: pooled results from two randomized, double-blind, placebo-controlled Phase 3 trials. Am J Gastroenterol 2011; 106(Suppl. 2): S504-6.
31. Quigley EM, Tack J, Chey WD et al. Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints. Aliment Pharmacol Ther 2013; 37: 49-61.
32. Macdougall JE, Johnston JM, Lavins BJ et al. An evaluation of the FDA Responder Endpoint for IBS-C clinical trials: analysis of data from linaclotide Phase 3 clinical trials. Neurogastroenterol Motil 2013; 25: 481-6.
33. Corsetti M, Tack J. FDA and EMA end points: which outcome end points should we use in clinical trials in patients with irritable bowel syndrome? Neurogastroenterol Motil 2013; 25: 453-7.
34. Videlock EJ, Cheng V, Cremonini F. Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis. Clin Gastroenterol Hepatol 2013; 11: 1084-92.